Ongoing Trials
67 pivotal ongoing oncology trials.
- CIRCULATE-US / NRG-GI008 — Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): A Phase II/III Study of Circulating Tumor DNA (ctDNA)-Guided Adjuvant Therapy in Resected Stage II/III Colon Cancer
- Alliance A011801 / CompassHER2 RD — The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
- ECOG-ACRIN EA1151 / TMIST — Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
- Alliance A212102 / MCED Biobank — Blinded Reference Set for Multicancer Early Detection Blood Tests
- EAY191 / ComboMATCH — Molecular Analysis for Combination Therapy Choice (ComboMATCH)
- NRG-CC005 / FORTE — Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)
- CALGB 8461 — Cytogenetic Studies in Acute Leukemia and Multiple Myeloma (CALGB 8461 cytogenetics companion program)
- KEYNOTE-B96 — Pembrolizumab plus paclitaxel, with or without bevacizumab, for platinum-resistant recurrent ovarian cancer
- KEYNOTE-D46 — Pembrolizumab monotherapy versus sacituzumab govitecan plus pembrolizumab in first-line PD-L1-high NSCLC
- KEYNOTE-905 / EV-303 — Perioperative pembrolizumab, with or without enfortumab vedotin, in cisplatin-ineligible muscle-invasive bladder cancer
- CheckMate 9DW — Nivolumab plus ipilimumab versus lenvatinib or sorafenib in first-line advanced hepatocellular carcinoma
- CheckMate 8HW — Nivolumab, with or without ipilimumab, versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer
- CheckMate 9DX — Adjuvant nivolumab versus placebo in hepatocellular carcinoma at high risk of recurrence after resection or ablation
- NSABP B-59 / GeparDouze — Neoadjuvant chemotherapy with atezolizumab or placebo in triple-negative breast cancer
- NRG-GY018 — Pembrolizumab added to paclitaxel and carboplatin in advanced or recurrent endometrial cancer
- CompassHER2-pCR / EA1181 — De-escalated neoadjuvant chemotherapy plus HER2-targeted therapy in HER2-positive breast cancer
- NCI-MATCH / EAY131 — Targeted therapy directed by tumor genetic testing across advanced cancers (basket trial)
- SWOG S1826 — Nivolumab-AVD versus brentuximab vedotin-AVD in advanced-stage classic Hodgkin lymphoma
- PRAGMATICA-LUNG / S2302 — Ramucirumab plus pembrolizumab versus standard care in previously treated NSCLC
- PDIGREE / A031704 — Response-adaptive nivolumab/ipilimumab then nivolumab, with or without cabozantinib, in advanced RCC
- BWEL / A011401 — Telephone-based weight-loss intervention after breast cancer
- ShortStop-HER2 — Six versus twelve months of HER2-targeted therapy in early HER2-positive breast cancer
- KEYNOTE-671 — Perioperative pembrolizumab with neoadjuvant chemotherapy in resectable stage II–IIIB NSCLC
- KEYNOTE-716 — Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
- CheckMate 274 — Adjuvant nivolumab versus placebo after radical surgery for high-risk muscle-invasive urothelial carcinoma
- NRG-GU009 / PREDICT-RT — Genomic-risk-adapted radiotherapy and hormonal therapy in high-risk prostate cancer
- NRG-LU007 / RAPTOR — Adding consolidative radiation to atezolizumab maintenance in extensive-stage small cell lung cancer
- NRG-GY019 — Letrozole with or without paclitaxel–carboplatin in newly diagnosed low-grade serous ovarian cancer
- NRG-BR007 / DEBRA — De-escalation of adjuvant radiation in low-risk, hormone-sensitive early breast cancer
- NRG-GI008 / CIRCULATE-US — Circulating-tumor-DNA-guided adjuvant chemotherapy in resected stage II–III colon cancer
- NRG-GU010 / GUIDANCE — Genomic-risk-adapted therapy in unfavorable intermediate-risk prostate cancer
- EA5163 / INSIGNA — Optimal timing and sequencing of pembrolizumab and chemotherapy in first-line non-squamous NSCLC
- EA2185 — Comparing high- versus low-intensity surveillance of pancreatic mucinous cysts
- EA8212 / BRIDGE — Intravesical BCG versus gemcitabine–docetaxel in high-grade non-muscle-invasive bladder cancer
- SWOG S1806 — Chemoradiation with or without atezolizumab for localized muscle-invasive bladder cancer
- Alliance A021806 — Perioperative versus adjuvant mFOLFIRINOX for resectable pancreatic cancer
- A031801 / RadiCaL — Adding radium-223 to cabozantinib for renal cell carcinoma with bone metastases
- A021703 / SOLARIS — Adding high-dose vitamin D3 to chemotherapy and bevacizumab in metastatic colorectal cancer
- KEYNOTE-B49 — Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for HR-positive/HER2-negative metastatic breast cancer
- NRG-GI011 — Dose-escalated radiation therapy for locally advanced pancreatic cancer
- A022101 / NRG-GI009 — Total ablative therapy added to systemic therapy for limited metastatic colorectal cancer (ERASur)
- A032302 — Androgen deprivation plus apalutamide with or without docetaxel in metastatic castration-sensitive prostate cancer (ASPIRE)
- A082304 / S2402 — Perioperative versus adjuvant systemic therapy in resectable non-small cell lung cancer (PROSPECT-Lung)
- HARMONi-2 — Ivonescimab versus pembrolizumab as first-line therapy for PD-L1-positive advanced NSCLC (HARMONi-2)
- HARMONi-3 — Ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic NSCLC (HARMONi-3)
- TROPION-Lung08 — Datopotamab deruxtecan plus pembrolizumab versus pembrolizumab in first-line PD-L1-high NSCLC (TROPION-Lung08)
- EV-304 / KEYNOTE-B15 — Perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer (EV-304)
- GLOW — Zolbetuximab plus CAPOX versus placebo plus CAPOX as first-line treatment of CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma (GLOW)
- MajesTEC-7 — Teclistamab or talquetamab plus daratumumab and lenalidomide versus daratumumab-lenalidomide-dexamethasone in transplant-ineligible newly diagnosed multiple myeloma (MajesTEC-7)
- MajesTEC-3 — Teclistamab in combination with daratumumab subcutaneously (Tec-Dara) versus daratumumab, pomalidomide, and dexamethasone (DPd) or daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma (MajesTEC-3)
- KarMMa-9 — Idecabtagene vicleucel plus lenalidomide maintenance versus lenalidomide maintenance after transplant in newly diagnosed multiple myeloma (KarMMa-9)
- EPCORE DLBCL-2 — Epcoritamab plus R-CHOP versus R-CHOP in first-line diffuse large B-cell lymphoma (EPCORE DLBCL-2)
- CELESTIMO — Mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma (CELESTIMO)
- AMPLIFY — Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemoimmunotherapy in first-line CLL (AMPLIFY)
- BREAKWATER — Encorafenib plus cetuximab, with or without chemotherapy, versus standard chemotherapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER)
- PROCEADE-CRC-03 — Precemtabart tocentecan with or without bevacizumab versus trifluridine/tipiracil plus bevacizumab in previously treated metastatic colorectal cancer (PROCEADE-CRC-03)
- DESTINY-Breast09 — Trastuzumab deruxtecan with or without pertuzumab versus taxane, trastuzumab, and pertuzumab in first-line HER2-positive metastatic breast cancer (DESTINY-Breast09)
- lidERA — Adjuvant giredestrant versus physician's choice of endocrine monotherapy in ER-positive, HER2-negative early breast cancer (lidERA Breast Cancer)
- KLK2-comPAS — Pasritamig versus placebo in late-line metastatic castration-resistant prostate cancer (KLK2-comPAS)
- TROPION-Breast02 — Datopotamab deruxtecan versus investigator's choice of chemotherapy in first-line, PD-L1-low, inoperable or metastatic triple-negative breast cancer (TROPION-Breast02)
- AVANZAR — Datopotamab deruxtecan plus durvalumab and carboplatin versus pembrolizumab plus platinum chemotherapy in first-line advanced non-small cell lung cancer (AVANZAR)
- CAMBRIA-1 — Camizestrant versus standard adjuvant endocrine therapy in intermediate- to high-risk ER-positive, HER2-negative early breast cancer (CAMBRIA-1)
- MATTERHORN — Perioperative durvalumab plus FLOT chemotherapy versus placebo plus FLOT in resectable gastric and gastroesophageal junction adenocarcinoma (MATTERHORN)
- PSMAfore — 177Lu-PSMA-617 radioligand therapy versus a switch of androgen-receptor pathway inhibitor in taxane-naïve metastatic castration-resistant prostate cancer (PSMAfore)
- AMPLITUDE — Niraparib plus abiraterone acetate and prednisone versus placebo plus abiraterone acetate and prednisone in HRR-mutated metastatic castration-sensitive prostate cancer (AMPLITUDE)
- CARTITUDE-5 — VRd induction followed by ciltacabtagene autoleucel versus VRd followed by lenalidomide-dexamethasone maintenance in newly diagnosed multiple myeloma not planned for transplant (CARTITUDE-5)
- ECHO — Acalabrutinib plus bendamustine-rituximab versus placebo plus bendamustine-rituximab in previously untreated mantle cell lymphoma (ECHO)